BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Dec. 22, 2004
View Archived Issues
Pharmos Crashes On Data From Phase III Brain Study
Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International)
Read More
CAT Wins Court Battle Over Humira; Abbott Logs Appeal
Read More
Gene Therapy Boosts Hope For Blood Disease Therapies
Read More
Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M
Read More
Europe Tackles Distinction In Similar Biotech Orphan Drugs
Read More
Phytopharm Product, Not Good For Pharma, Aimed At Foods
Read More
'Right Time': Bavarian Nordic To Form Cancer Vaccine Unit In U.S.
Read More
NicOx Taking Lead CINOD Into Phase III Osteoarthritis Program
Read More
Metabolic Jumps, Slides On Trial Data, Analyst Criticism
Read More
Santhera Raises Additional EUR7M In Second Closing Of Financing
Read More
Other News To Note
Read More